Toshiba's CorE 64 Multi-Center Study Completes Enrollment.Largest International Multi-Center 64-Slice CT Trial; Benefits of Findings Evidenced by Use in Two Ancillary Studies Presented at ACC See adaptive cruise control. TUSTIN, Calif. -- Toshiba America Medical Systems, Inc. today announced the completion of enrollment for 400 patients in its CorE 64 (Coronary Evaluation on 64) study taking place across seven countries, the largest trial ever initiated evaluating the use of 64-slice CT technology. The trial's enrollment completion signifies that the study of all patient participants has finished, resulting in the most statistically reliable data available to date. Toshiba's CorE 64 trial investigates the use of multi-slice CT as the primary diagnostic tool for detecting cardiovascular diseases and disorders, as compared to cardiac catheterization, a costly, invasive technique. Data collected to date from CorE 64 indicates CT holds a favorable place as a diagnostic alternative to cardiac catheterization and has the potential to change the delivery of healthcare. "We expect CorE 64 findings to impact the overall reimbursement guidelines for multi-slice CT, resulting in greater patient access to these exams and to have significant economic benefits for 64-slice CT," explained Toshihiro Rifu, senior fellow, Toshiba Medical Systems Corporation. "Additional benefits from this study are already evidenced by the use of CorE 64's preliminary data in two ancillary studies by Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. presented at American College of Cardiology The American College of Cardiology (ACC) is a nonprofit medical association established in 1949 to educate, research and influence health care public policy. The president for the 2006–2007 year is Steven E. Nissen. [1] The organization has 39 chapters in the U.S. (ACC) annual meeting." The CorE 64 multi-center study participants include nine sites across seven countries: * Johns Hopkins University School of Medicine The Johns Hopkins University School of Medicine, located in Baltimore, Maryland, USA, is a highly regarded medical school and biomedical research institute in the United States. , in Baltimore, Md., led by primary investigators Drs. Joao A. C. Lima and Julie Miller * Johns Hopkins Bayview Medical Center Johns Hopkins Bayview Medical Center, formerly known as Francis Scott Key Medical Center and Baltimore City Hospital, is a hospital and medical office center in East Baltimore. It is located along Eastern Avenue near Bayview Boulevard. in Baltimore, Md. * Beth Israel Deaconess Medical Center Both an international and regional referral center, Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a major teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and at Harvard in Boston, Mass. * Leiden University Medical Center The Leiden University Medical Center (Dutch: Leids Universitair Medisch Centrum) or LUMC, is the university hospital affiliated with Leiden University, of which it forms the medical faculty. in the Netherlands * Humboldt University, Campus Charite Mitte in Germany * INCOR Heart Institute of the School of Medicine Hospital, Sao Paulo University in Brazil * Iwate Medical University in Japan * Mount Elizabeth Hospital Mount Elizabeth Hospital and Medical Centre (Chinese: 伊丽莎白医院) is a private hospital in Singapore. in Singapore * Toronto General Hospital The Toronto General Hospital (TGH), part of the University Health Network, is a major teaching hospital in downtown Toronto, Canada. It is located in the Discovery District, directly north of the Hospital for Sick Children, across Gerrard Street West, and east of Princess , University Health Network and Mount Sinai Hospital Mount Sinai Hospital can refer to:
According to Toshiba's senior director of CT, Doug Ryan, the CorE 64 clinical trial utilizes a different approach when compared to previous studies on the topic. This is attributed in large part to the study's unique design, which calls for an international, multi-center approach, bypassing limitations associated with previous studies that focus on one geographic area or utilize smaller patient populations. "CorE 64 is the first trial that evaluates all of its 400 study participants who are between 50 and 70 percent stenotic, resulting in statistically significant data," noted Ryan. "We anticipate CorE 64 will set a precedent for all future CT trials conducted by Toshiba and by other leaders in the medical field." For more information about CorE 64, please visit www.medical.toshiba.com. About Toshiba With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corp., an independent group company of Toshiba Corp., is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, Cath & EP Labs, X-ray, Ultrasound, Nuclear Medicine, MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. and information systems. Toshiba Corp. is a leader in information and communications systems, electronic components, consumer products, and power systems. Toshiba has approximately 172,000 employees worldwide and annual sales of $62 billion. For more information, visit www.medical.toshiba.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion